Additive effects of enalapril and losartan in (mREN-2)27 transgenic rats

Hypertension

Volumn 31, Issue 2, 1998, Pages 692-698

  Richer, Christine ^a   Bruneval, Patrick ^b   Ménard, Joël ^c   Giudicelli, Jean François ^b,c  

^a Département de Pharmacologie   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c INSERM   (France)

Author keywords

Enalapril; Losartan; Rats, TGR(mREN2)27; Renin angiotensin system

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LOSARTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MIXTURE; DRUG POTENTIATION; HEART VENTRICLE HYPERTROPHY; HYPERTENSION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

EID: 0031934185     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.31.2.692     Document Type: Article

References (28)

1. Juillerat L, NussbergerJ, Ménard J, Mooser V, Christen Y, Waeber B, Graf P, Brunner HR. Determinants of angiotensin II generation during converting enzyme inhibition. Hypertension. 1990;16:564-572.
2. Van den Meiracker AH, Man in't Veld AJ, Admiraal PJJ, Ritsema Van Eck HJ, Boomsma F, Derkx FHM, Schalekamp MADH. Partial escape of angiotensin converting enzyme (ACE) inhibition during prolonged ACE inhibitor treatment: does it exist and does it affect the antihypertensive response? J Hypcrtaa. 1992;10:803-812.
3. Urata H, Healy B, Stewart RW, Bumpus FM, Husain A. Angiotensin H-fomiing pathways in normal and failing human hearts. Circ Res. 1990; 66:883-890.
4. Okunishi H, Miyazaki M, Toda N. Evidence for a putatively new angiotensin II-generating enzyme in the vascular wall. J Hypertem. 1984;2: 277-284.
5. Azizi M, Chatellier G, Guyene T, Murieta-Geofiroy D, Ménard J. Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives. Circulation. 1995;92:825-834.
6. Cachofeiro V, Maeso R, Rodrigo E, NavarroJ, Ruilope LM, Lahera V. Nitric oxide and prostaglandins in the prolonged effects of losartan and ramipril in hypertension. Hypertension. 1995;26:236-243.
7. Jaiswal N, Diz DI, Tallant EA, Khosla MC, Ferrario CM. The nonpeptide angiotensin II antagonist DUP 753 is a potent stimulus for prostacyclin synthesis. Am J Hypautu. 1991;4:228-233.
8. Azizi M, Guyene TT, Chatellier G, Wargon M, Ménard, J. Additive effects of losartan and enalapril on blood pressure and plasma active renin. Hypertension. 1997;29:634-640.
9. Ménard J, Campbell DJ, Azizi M, Gonzales MF. Synergistic effects of ACE inhibition and Ang II antagonism on blood pressure, cardiac weight, and renin in spontaneously hypertensive rats. Circulation. 1997;96:3072-3078.
10. Bachmann S, Peters J, Engler E, Ganten D, Mullins JJ. Transgenic rats carrying the mouse renin gene: morphological characterization of a low-renin hypertension model. Kidney Int. 1992;41:24-36.
11. Tokita Y, Franco-Saenz R, Reimann EM, Mulrow PJ. Hypertension in the transgenic rat TGR(mRen-2)27 may be due to enhanced kinetics of the reaction between mouse renin and rat angiotensinogen. Hypertension. 1994;23:422-427.
12. Campbell DJ, Rong P, Kladis A, Rees B, Ganten D, Skinner SL. Angiotensin and bradykinin peptides in the TGR(mRen-2)27 rat. Hypertension. 1995;25:1014-1020.
13. Peters J, Hilgers KF, Maser-Gluth C, Kreutz R. Role of the circulating renin-angiotensin system in the pathogenesis of hypertension in transgenic rats, TGR (mREN2)27. Clin Exp Hypcnms. 1996:18:933-948.
14. Mullins JJ, Peters J, Ganten D. Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 gene. Nature. 1990:344:541-544.
15. Lemmer B, Witte K, Makabe T, Ganten D, Mattes A. Effects of enalaprilat on circadian profiles in blood pressure and heart rate of spontaneously and transgenic hypertensive rats. J Cardiovasc Pliarmarol. 1994;23:311-314.
16. Michel JB, Dussaule JC, Choudat L, Auzan C, Nochy D, Corvol, P. Ménard J. Effects of antihypertensive treatment in one-clip, two-kidney hypertension in rats. Kidney Int. 1986:29:1011-1020.
17. Ferguson RK, Drunner HR, Turini GA, Gavras H, McKinstry DN. A specific orally active inhibitor of angiotensin converting enzyme in man. Lancet. 1977;l:775-778.
18. Christen Y, Waeber B, Nussberger J, Porchet M, Borland RM, Lee RJ, Maggon K, Shum L, Timmermans PBMWM, Brunner HR. Oral administration of DUP 753, a specific angiotensin II receptor antagonist, to normal male volunteers: inhibition of pressor response to exogenous angiotensin I and II. Circulation. 1991;83:1333-1342.
19. Tokita Y, Franco-Saenz R, Mulrow PJ. Reversal of the suppressed kidney renin level in the hypertensive transgenic rat TGR (mRen-2)27 by angiotensin converting enzyme inhibition. AmJ Hypertens. 1995;8:1031-1039.
20. Bunag RD, Butterfield J. Tail-cuff blood pressure measurement without external preheating in awake rats. Hypertension. 1982;4:898-903.
21. Richer C, Lefevre-Borg F, Lechaire J, Gomeni C, Gomeni R, Giudicelli JF, Cavero I. Systemic and regional hemodynamic characterization of alpha-1 and alpha-2 adrenoceptor agonists in pithed rats. J Plumnjcol Exp Tlier. 1987;240:944-953.
22. Clauser EJ, Bouhnik MF, Gonzales P, Corvol P, Ménard J. Influence of converting-enzyme inhibition on rat des-angiotensin I-angiotensinogen. Am J Physiol. 1984;246:E129-E133.
23. Veniant M, Whitworth CE, Ménard J, Sharp MGF, Gonzales MF, Bruneval P, Muffins JJ. Developmental studies demonstrate age-dependent elevation of renin activity in TGR(mRen2)27 rats. Am] Hypcttens. 1995;8:1167-1176.
24. Ménard J, Catt KJ. Measurement of renin activity, concentration and substrate in rat plasma by radioimmunoassay of angiotensin I. Endocrinology. 1972;90:422-430.
25. Bradford H. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biodiem. 1976;72:248-254.
26. Veniant M, Ménard J, Bruneval P, Morlcy S, Gonzales MF, Mullins JJ. Vascular damage without hypertension in transgenic rats expressing prorenin exclusively in the liver. J Clin Invest. 1996;98:1966-1970.
27. Bruneval P, Sassy C, Mayeux P, Belair MF, Casadevall N, Roux FX, Varet B, Lacombe C. Erythropoietin synthesis by tumor cells in a case of meningioma associated with erythrocytosis. Blood. 1993;81:1593-1597.
28. LudbrookJ. Repeated measurements and multiple comparisons in cardiovascular research. Cmdiovofc Res. 1994;28:303-311.